Metropolitan Life Insurance CO Graphite Bio, Inc. Transaction History

Metropolitan Life Insurance CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.14 - $5.23 $5,050 - $12,342	-2,360 Closed	0 $0
Q1 2022 Jun 20, 2023	BUY	$5.1 - $13.06 $12,036 - $30,821	2,360 New	2,360 $12,000
Q1 2022 Mar 30, 2023	SELL	$5.1 - $13.06 $14,438 - $36,972	-2,831 Reduced 54.54%	2,360 $12,000
Q1 2022 May 12, 2022	BUY	$5.1 - $13.06 $12,036 - $30,821	2,360 New	2,360 $12,000
Q4 2021 Feb 15, 2022	SELL	$8.41 - $16.71 $43,656 - $86,741	-5,191 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$15.81 - $28.39 $82,069 - $147,372	5,191 New	5,191 $85,000
Q3 2021 Mar 30, 2023	BUY	$15.81 - $28.39 $82,069 - $147,372	5,191 New	5,191 $85,000
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $82,069 - $147,372	5,191 New	5,191 $85,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.